Could a Pre-Surgery drug improve thyroid cancer outcomes?

NCT ID NCT04321954

Completed Disease control Sponsor: Massachusetts Eye and Ear Infirmary Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving the drug lenvatinib before surgery helps remove advanced thyroid cancer more completely. 29 adults with invasive thyroid cancer took lenvatinib for a short time before their operation. The goal was to see if more patients could have clear or nearly clear surgical margins, which may improve long-term control of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib (Lenvima), a drug taken orally
What this could lead to: If successful, this could make surgery for advanced thyroid cancer more effective by shrinking tumors beforehand, potentially leading to better outcomes.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. Lenvatinib can cause side effects like high blood pressure and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer differentiated thyroid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER DIFFERENTIATED THYROID CANCER

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.